Edition:
India

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

6.35EUR
15 Feb 2019
Change (% chg)

€0.03 (+0.47%)
Prev Close
€6.32
Open
€6.26
Day's High
€6.39
Day's Low
€6.21
Volume
95,661
Avg. Vol
387,234
52-wk High
€9.44
52-wk Low
€4.41

Latest Key Developments (Source: Significant Developments)

Innate Pharma Announces Appointment Of Laure-Helene Mercier To Executive Board
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA ANNOUNCES APPOINTMENT OF LAURE-HÉLÈNE MERCIER TO THE EXECUTIVE BOARD.  Full Article

Innate Pharma Receives FDA Fast Track Designation For IPH4102
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME.FTD IS BASED ON THE EVALUATION OF PHASE I RESULTS DEMONSTRATING STRONG CLINICAL ACTIVITY, FAVORABLE SAFETY AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE.TELLOMAK, A GLOBAL, MULTI-COHORT, PHASE II STUDY EVALUATING POTENTIAL OF IPH4102 IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS, WILL BE INITIATED IN H1 2019.  Full Article

Innate Pharma Announces Publication Of Monalizumab Research In "Cell" Journal
Friday, 30 Nov 2018 

Nov 30 (Reuters) - INNATE PHARMA SA ::PUBLICATION OF MONALIZUMAB RESEARCH IN "CELL" JOURNAL.PUBLICATION REPORTS THAT MONALIZUMAB STIMULATES SIMULTANEOUSLY ANTI-TUMOR ACTIVITY OF NK CELLS AND T CELLS.COMBINATION OF THEIR NKG2A BLOCKING ANTIBODY WITH A PD-L1 BLOCKING ANTIBODY PROVIDES AN ADDITIVE EFFECT TOWARDS ACTIVATION OF AN ANTI-TUMOR IMMUNITY.MONALIZUMAB CETUXIMAB COMBINATION IS WELL TOLERATED AND PROVIDES ENCOURAGING EFFICACY RESULTS.  Full Article

Innate Pharma End-Q3 Cash Of EUR 131.7 Million
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - INNATE PHARMA SA ::END-Q3 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS EUR 131.7 MILLION.Q3 REVENUE IFRS 15 EUR ‍​5.6 MILLION VERSUS EUR 5.8 MILLION RESTATED YEAR AGO.RECRUITMENT OF THE FIRST PATIENT IN PHASE I STUDY EVALUATING IPH5401 IN ONCOLOGY.TOLERANCE DATA FOR IPH5401 EXPECTED IN H2 OF 2019.PHASE II PROGRAM TESTING OF IPH4102 FOR MULTIPLE TYPES OF T-TYPE LYMPHOMA WILL BE INITIATED IN H1 OF 2019.  Full Article

Astrazeneca Announced New Multi-Term Agreement With Astrazeneca
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA STRENGTHENS AND EXPANDS ITS ONCOLOGY DEVELOPMENT COLLABORATION WITH ASTRAZENECA.INNATE PHARMA ACQUIRES US AND EU RIGHTS TO COMMERCIALIZE LUMOXITI TO BECOME A FULLY-INTEGRATED ONCOLOGY-FOCUSED BIOTECH.ASTRAZENECA OBTAINS FULL ONCOLOGY RIGHTS TO MONALIZUMAB.ASTRAZENECA GAINS ACCESS TO INNATE PHARMA'S ANTI-CD39 MONOCLONAL ANTIBODY, IPH5201, PLUS FOUR ADDITIONAL IMMUNO-ONCOLOGY MOLECULES.ASTRAZENECA TO PURCHASE NEWLY-ISSUED EQUITY STAKE OF 9.8% IN INNATE PHARMA.  Full Article

Astrazeneca Expands Oncology Collaboration With Innate Pharma
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - AstraZeneca Plc ::ASTRAZENECA EXPANDS ONCOLOGY DEVELOPMENT AND COMMERCIALISATION COLLABORATION WITH INNATE PHARMA.WILL OBTAIN FULL ONCOLOGY RIGHTS TO HUMANISED ANTI-NKG2A ANTIBODY, MONALIZUMAB.ALSO GAINS OPTION RIGHTS TO IPH5201, ANTIBODY TARGETING CD39, & FOUR PRECLINICAL MOLECULES FROM INNATE'S PIPELINE.INNATE WILL PAY ASTRAZENECA $50 MILLION UPFRONT FOR LUMOXITI.INNATE TO PAY $25 MILLION FOR CERTAIN FUTURE MILESTONES FOR INTELLECTUAL PROPERTY AND CLINICAL AND MANUFACTURING DEVELOPMENT OF LUMOXITI.  Full Article

Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer
Saturday, 20 Oct 2018 

Oct 22 (Reuters) - INNATE PHARMA ::INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER.CONFIRMATION OF PREVIOUSLY REPORTED RESPONSE RATE AND NEW DATA ON DURABILITY OF RESPONSE REINFORCES THE POTENTIAL ANTI-TUMOR ACTIVITY OF THE MONALIZUMAB CETUXIMAB COMBINATION.CLINICAL PROGRAM ADVANCES WITH EXPANSION COHORT IN PATIENTS PREVIOUSLY TREATED WITH PD-1/L1 THERAPIES.IN STUDY EVALUATING COMBINATION OF MONALIZUMAB AND CETUXIMAB OVERALL RESPONSE RATE WAS 27.5% (BY RECIST) INCLUDING 1 CONFIRMED COMPLETE RESPONSE (2.5%) AND 10 PARTIAL RESPONSES (25%).DISEASE CONTROL RATE AT 24 WEEKS (DCR) WAS 35%.MEDIAN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) REACHED 5.0 AND 10.3 MONTHS, RESPECTIVELY.IN ADDITION, THERE WERE 3 (18%) RESPONDERS AMONG 17 PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH PD-1/L1 ANTIBODIES.AMONG 40 PATIENTS ENROLLED IN COHORT EXPANSION, SAFETY FINDINGS WERE CONSISTENT WITH PREVIOUSLY PRESENTED DATA AT AACR 2017 AND 2018, WITH NO ADDITIONAL SAFETY CONCERNS COMPARED TO MONALIZUMAB OR CETUXIMAB GIVEN ALONE.  Full Article

Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN
Wednesday, 18 Apr 2018 

April 17 (Reuters) - INNATE PHARMA SA ::PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN.8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL.NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED.COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS.TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED.  Full Article

Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD.  Full Article

Eric Vivier Joins Innate Pharma As Chief Scientific Officer
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.  Full Article

BRIEF-Innate Pharma Announces Updated Results On IPH4102

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME